Christopher S. Henney has been appointed chairman of the board of Anthera Pharmaceuticals Inc. (San Mateo, CA).
Christopher S. Henney has been appointed chairman of the board of Anthera Pharmaceuticals Inc. (San Mateo, CA). Henney has served as an independent director of Anthera since 2006. He is a co-founder of three major publicly held US biotechnology companies: Immunex‚ ICOS, and Dendreon‚ and has been associated with the formation of several others. Most recently Henney has served as chairman and CEO of Dendreon, and as chairman of SGX Pharmaceuticals and of Oncothyreon.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
Novel Modalities Spur Shift in Outsourcing Processes and Partnerships
May 8th 2025While a one-stop shop still has its advantages, sponsor companies and CDMOs are starting to see each other not as transactional relationships, but true partners with a common goal of getting drugs to patients faster.
Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing
May 7th 2025The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.